LSTA

Business Context and Reporting Period

Company: NeoStem, Inc. (formerly Lisata Therapeutics, Inc. in metadata, but filing identifies NeoStem, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2008.
Business Overview: NeoStem operates a commercial autologous adult stem cell bank, managing a network of collection centers in major U.S. metropolitan areas. The company also holds an exclusive worldwide license for VSEL (very small embryonic-like) stem cell technology. The company is classified as a smaller reporting company.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2008):
- Net cash used in operating activities: $(2,698,136)
- Net cash used in investing activities: $(2,379)
- Net cash provided by financing activities: $925,383 (primarily from a $900,000 private placement in May 2008).

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 61% year-over-year (from $61,912 to $24,221) due to a reduction in startup fees collected from physicians as the company shifted focus from recruiting new physicians to recruiting clients into existing centers.
• Increased Operating Loss: Net loss increased by approximately 30% year-over-year. While cash-funded operating expenses decreased slightly, total operating expenses rose by 28% primarily due to a significant increase in non-cash stock-based compensation ($1.2 million vs. $574k in the prior period).
• Liquidity Improvement: Cash balances increased from $85,382 in June 2007 to $529,095 in June 2008, driven by the May 2008 private placement of securities raising $900,000.
• Share Count: Weighted average shares outstanding increased significantly (from ~2.56 million to ~5.20 million) due to equity issuances for services and financing.

Outlook, Risks, and Management Commentary

• Capital Needs: Management states the company will need to raise additional capital or acquire a revenue-generating business within the next 12 months to fund operations. There is no assurance that funding will be available on acceptable terms.
• Cost Conservation: In August 2008, several senior management and staff members voluntarily deferred salary until additional capital is raised.
• Strategic Focus: The company is actively identifying acquisition targets or collaborative arrangements. New collection center agreements were signed in NYC, Santa Monica, and Coral Gables, with operations anticipated in late 2008.
• R&D Obligations: The company has obligations under a Sponsored Research Agreement (SRA) for VSEL technology totaling $375,000, with payments contingent on research commencement (pending IRB approvals).
• Risks: Significant risks include the ability to manage the business despite continuing losses, the inability to obtain sufficient capital, and the failure to secure regulatory approvals or patents for VSEL technology.

Investor Verification Checklist

• Cash Runway: Verify if the $529,095 cash balance is sufficient to cover the $2.7M operating cash burn rate observed in the first half of 2008 without immediate new financing.
• Revenue Sustainability: Confirm the operational status and revenue generation of the new collection centers signed in NYC, Santa Monica, and Florida.
• Dilution Risk: Review the impact of outstanding warrants (3.17 million shares) and options (1.78 million shares) on future share count and ownership dilution.
• Related Party Transactions: Scrutinize the extensive use of stock issuances to pay consultants, executives, and advisors, which significantly inflated operating expenses.
• VSEL Milestones: Monitor the status of IRB approvals required to commence the VSEL research and trigger the $375,000 payment obligation.